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Mechanical cardiac circulatory support has been established as a benefactory treat-
ment modality for patients with end stage heart failure. There is a variety of ventricular 
assist devices (VAD) that are available for implantation depending on patients’ clinical 
characteristics, type of heart failure and intention of treatment. Current indications of 
VAD placement are: a) bridge to transplant, for patients who are transplant candidates 
but who will not survive waiting until an organ is available, b) destination therapy, for 
patients who are not transplant candidates, c) bridge to recovery, for patients in whom 
the native heart function may possibly recover.
Patient selection and timing of implantation are the most important predictors of 
the final outcome. VAD therapy should not be offered to those patients with advanced 
heart failure until all other medical options have been explored. However, it should 
be implemented before profound and non reversible hemodynamic decompensation 
and end-organ failure occurs.
Cardiac support with a left ventricular assist device has showed a 34% increase 
in survival to transplantation in bridge-to-transplant patients when compared with 
conventional medical therapy.1 Moreover Deng et al compared elective, urgent and 
emergent VAD implantation and showed that mortality was worse in the latter group 
of patients.2 Additionally from the INTERMACS database, it is evident that patients 
in a more critical condition at implantation experienced worse survival rates than more 
stable patients.3 Alba et al showed that those at INTERMACS levels 1 and 2 (more 
profound heart failure decompensation) have nearly a threefold higher mortality risk 
when having assist devices implanted compared with those at levels 3 and 4 (moderate 
heart failure symptoms).4
The REMATCH trial was the first clinical prospective randomized trial to 
examine survival difference between patients with end stage heart failure receiving 
VAD treatment and those receiving conventional medical therapy. The former group 
experienced a 52% one-year and 25% two-year survival rate and the latter 25% and 
8% respectively.5 In the INTrEPID trial investigators enrolled more critically ill heart 
failure patients in comparison with REMATCH (the majority were in inotropic sup-
port). 1-year survival was 27% and 11% for patients in the VAD arm and the medical 
arm respectively.6 Therefore the advanced heart failure patients who are expected to 
benefit more from VAD implantation are those who are not on intravenous inotropic 
support7, or intraaortic balloon pump8, have not severe renal dysfunction9 and can 
tolerate angiotensin-converting enzyme inhibitors or other vasodilators10.
Mechanical circulatory assistance as bridge to recovery is mainly considered for 
acutely decompensated heart failure due to reversible causes, such as acute myocardial 
infarction, myocarditis, postcardiotomy shock and peripartum cardiomyopathy.11 Data 
from more recent studies have raised issues concerning the potential beneficial effect 
of the mid-, long-term ventricular support in chronic heart failure patients as well, that 
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can lead to the weaning of VAD finally. The HARPS trial is 
expected to shed light in this field. In many cases, the initial 
indication for VAD implantation changes during patient’s sup-
port. Patients may improve or change their clinical condition 
(e.g., renal dysfunction, obesity or pulmonary hypertension) 
and become suitable for another VAD indication (bridge to 
decision or bridge to candidacy).
The technologic evolution of assist devices and the ex-
pansion and development of dedicated circulatory support 
programs with significant volume load make future look more 
promising. It appears that long-term mechanical assistance 
will approach heart transplant survival rates quite soon, be-
coming more attractive as an alternative for end stage heart 
failure patients.
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